ライフサイエンスコーパス: dry mouth

1 abdominal pain, constipation, dizziness, and dry mouth.

2 re insomnia, decreased appetite, nausea, and dry mouth.

3 uld improve sensitivity for the diagnosis of dry mouth.

4 s included sedation, change in appetite, and dry mouth.

5 when patients had not only dry eye but also dry mouth.

6 bo groups were dyskinesia, constipation, and dry mouth.

7 verse effects on the salivary gland, such as dry mouth.

8 ith a 2- to 3-year history of stomatitis and dry mouth.

9 immune disease characterized by dry eyes and dry mouth.

10 The most common adverse events were dry mouth (24 [2%], 67 [13%], and 207 [21%] in the group

11 placebo, including fatigue (30% vs. 14%) and dry mouth (25% vs. 12%) in the amitriptyline group and p

12 ded hyperphosphatemia (65%), asthenia (55%), dry mouth (45%), nail toxicity (35%), constipation (34%)

13 e anticholinergic group had a higher rate of dry mouth (46% vs. 31%, P=0.02) but lower rates of cathe

14 recipients), somnolence (5.1% vs. 1.5%), and dry mouth (5.1% vs. 0.8%) were the most frequently repor

15 ng symptoms were more frequent at 12 months: dry mouth (58% v 17%), difficulties tasting (32% v 8%),

16 nation of sicca complex (marked dry eyes and dry mouth), abnormal pupillary light response, upper gas

17 ), without differences in the development of dry mouth, altered taste, or salivary gland pain.

18 Adverse effects were generally mild (eg, dry mouth and cough).

19 salivation, dizziness, and sweating and less dry mouth and decreased appetite than those treated with

20 Dimebon was well tolerated: dry mouth and depressed mood or depression were the most

21 the salivary and lacrimal glands, leading to dry mouth and dry eyes.

22 ctive assessment of the specific symptoms of dry mouth and dry eyes.

23 abial and lacrimal--leading to complaints of dry mouth and eyes.

24 prototypical drug used to treat glaucoma and dry mouth and is classified as either a full or partial

25 ell-characterized patients with dry eyes and dry mouth and lip biopsies from the Sjogren's Internatio

26 g onabotulinumtoxinA was less likely to have dry mouth and more likely to have complete resolution of

27 Complaints of dry mouth and tachycardia were significantly more freque

28 f exocrine tissues, resulting in xerostomia (dry mouth) and keratoconjunctivitis sicca (dry eyes).

29 y and lacrimal glands leading to xerostomia (dry mouth) and xerophthalmia (dry eyes).

30 onstipation, thirst, leg swelling, numbness, dry mouth, and balance problems.

31 useful for drug therapy of cystic fibrosis, dry mouth, and gastrointestinal hypomotility disorders,

32 ed with tolvaptan included increased thirst, dry mouth, and increased urination.

33 h cotherapy were unpleasant taste, headache, dry mouth, and somnolence.

34 tension, and symptoms such as palpitations, dry mouth, and sweating.

35 Somnolence, dizziness, dry mouth, and weight gain occurred significantly more o

36 Headache; pain in the mouth, lips, or gums; dry mouth; and sinus infection, pain, or discharge were

37 reasing number of the population suffer from dry mouth as a result of taking prescription drugs, with

38 In patients with dry eyes and dry mouth but F = 0, increased expression of anti- CA6 w

39 UWMS mucin concentrations are not reduced in dry mouth but that the mucin structure (glycosylation) i

40 Tolvaptan caused increased thirst and dry mouth, but frequencies of major adverse events were

41 oms and subjective measures of stiffness and dry mouth, but the increases in systolic blood pressure

42 The prevalence of dry-mouth complaint, the absence of saliva upon palpatio

43 significantly higher incidence of headache, dry mouth, constipation, insomnia, and dizziness.

44 Gene therapy for dry mouth disorders has transitioned in recent years fro

45 only possible drug related AEs reported were dry mouth, dizziness and anxiety in one patient and hypo

46 8 incidences of adverse effects (eg, nausea, dry mouth, dizziness, anxiety), whereas the acupuncture

47 odifications included constipation, fatigue, dry mouth, dizziness, nausea, anorexia, arrhythmia, head

48 Over 90% of patients with dry mouth (DMPs) consistently had unstimulated whole mou

49 as well as improving subjective symptoms of dry mouth, dry eyes, and overall dryness.

50 mozygous for the CA12(E143K) mutation have a dry mouth, dry tongue phenotype.

51 and lacrimal gland dysfunction resulting in dry mouth/dry eye syndrome, remains ill-defined.

52 timate (hazard ratio [HR] = 0.92; P = .004), dry mouth (HR = 5.1; P < .0001), alkaline phosphatase mo

53 erties between sufferers and nonsufferers of dry mouth in order to understand the relationship betwee

54 ere was a higher incidence of late-occurring dry mouth in patients who were given venlafaxine than in

55 is to determine whether acupuncture relieves dry mouth in this population.

56 The subjective feeling of dry mouth increased (P = 0.001).

57 Significantly more weight gain and cases of dry mouth, increased appetite, and somnolence were repor

58 uently during treatment with olanzapine were dry mouth, increased appetite, and somnolence.

59 during olanzapine treatment were somnolence, dry mouth, increased appetite, weight gain, akathisia, a

60 Es) reported by 10% of LDX participants were dry mouth, insomnia, and headache.

61 Xerostomia, or dry mouth, is a common side effect of head and neck radi

62 Dry mouth may indicate periodontal bone loss in children

63 cts of the drug (e.g., headache, somnolence, dry mouth, nausea, and dizziness).

64 oderate in severity; insomnia, constipation, dry mouth, nausea, dizziness, hot flush, headache, hyper

65 Common AEs included dizziness, dry mouth, nausea, fatigue, somnolence, euphoria, vomiti

66 ar component of SS, but not with symptoms of dry mouth or dry eyes.

67 was three times more common among those with dry mouth (OR = 3.05; 95% CI = 1.07 to 8.70).

68 ding (P <0.001), pain on chewing (P <0.001), dry mouth (P <0.001), and oral burning sensations (P <0.

69 global assessment of dry eyes (P = 0.0453), dry mouth (P = 0.0004), and increased salivary flow (P =

70 , logistic dose-response curve) but not with dry mouth (P = 0.63), altered taste (P = 0.27), or saliv

71 tolvaptan were pollakiuria, thirst, fatigue, dry mouth, polydipsia, and polyuria.

72 a was assessed based on "yes" responses to a dry-mouth questionnaire.

73 Xerostomia is defined as dry mouth resulting from a change in the amount or compo

74 up was associated with a higher incidence of dry mouth (RR=13.0, NNH=5) and sedation (RR=4.59, NNH=5)

75 a, conditions or medications associated with dry mouth, salivary gland enlargement or pregnancy were

76 were clinically significant improvements in dry-mouth-specific and global quality of life scores.

77 domains: subjective or objective measures of dry mouth, subjective or objective measures of dry eyes,

78 a for treatment of salivary hypofunction and dry mouth symptoms in primary Sjogren's syndrome patient

79 A total of 289 patients with dry mouth symptoms were evaluated.

80 analog scale questionnaires for dry eye and dry mouth symptoms, lissamine green ocular dye staining

81 Apart from changes over the trial in dry mouth symptoms, no significant differences were note

82 ffer from a devastating side effect known as dry-mouth syndrome, which results from the irreversible

83 r purified mucins for saliva substitutes and dry mouth therapy.

84 nzapine cotherapy group included somnolence, dry mouth, weight gain, increased appetite, tremor, and

85 ache, constipation, dizziness, vomiting, and dry mouth were also more frequent in the naltrexone plus

86 d to chewing, being understood, tasting, and dry mouth were placed in the top three by less than 10%

87 far-reaching consequences, as observed with dry mouth, which is associated with increased orodental

88 Complaints of a dry mouth (xerostomia) and sialoadenitis are frequent si

89 eck cancer patients that suffer from chronic dry mouth (xerostomia) due to salivary gland injury from

90 ggest that such an effect could underlie the dry mouth (xerostomia) that occurs as an unexplained sid

91 th dry eyes (keratoconjunctivitis sicca) and dry mouth (xerostomia).